identification of circulating micrornas for the differential diagnosis of parkinson’s disease and multiple system atrophy.
Clicks: 357
ID: 155517
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
357 views
48 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #26 of 395 articles by views in macromolecular bioscience
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 395 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. Parkinson's disease (PD) is a progressive neurodegenerative disorder which may be misdiagnosed with atypical conditions such as Multiple System Atrophy (MSA), due to overlapping clinical features. MicroRNAs (miRNAs) are small noncoding RNAs with a key role in post-transcriptional gene regulation. We hypothesized that identification of a distinct set of circulating miRNAs (cmiRNAs) could distinguish patients affected by PD from MSA and healthy individuals. Results. Using TaqMan Low Density Array technology, we analysed 754 miRNAs and found 9 cmiRNAs differentially expressed in PD and MSA patients compared to healthy controls. We also validated a set of 4 differentially expressed cmiRNAs in PD and MSA patients versus controls. More specifically, miR-339-5p was downregulated, whereas miR-223*, miR-324-3p and mir-24 were upregulated in both diseases. We found cmiRNAs specifically deregulated in PD (downregulation of miR-30c and miR-148b) and in MSA (upregulation of miR-148b). Finally, comparing MSA and PD, we identified 3 upregulated cmiRNAs in MSA serum (miR-24, miR-34b, miR-148b). Conclusions. Our results suggest that cmiRNA signatures discriminate PD from MSA patients and healthy controls and may be considered specific, non-invasive biomarkers for differential diagnosis.
| Reference Key |
evallelunga2014frontiersidentification
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Annamaria eVallelunga;Marco eRagusa;Stefania eDi Mauro;Tommaso eIannitti;Manuela ePilleri;Roberta eBiundo;Luca eWeis;Cinzia eDi Pietro;Angela eDe Iuliis;Alessandra eNicoletti;Mario eZappia;Michele ePurrello;Angelo eAntonini |
| Journal | macromolecular bioscience |
| Year | 2014 |
| DOI |
10.3389/fncel.2014.00156
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.